The South African government, in collaboration with the Gates Foundation and Wellcome Trust, has pledged R600 million ($33 million) to ensure the continuity of vital medical research initiatives, including a key HIV vaccine trial, in light of substantial reductions in US funding for these efforts.
This funding comprises R400 million from the government over three years, along with R100 million contributions from each of the foundations. It will primarily support research projects that have lost funding, especially those targeting diseases like AIDS and tuberculosis, as announced by the South African Medical Research Council on Monday.
Read: Slow motion denialism: Our leaders are allowing the HIV response to collapse
ADVERTISEMENT
CONTINUE READING BELOW
“We intend to apply for and hopefully secure additional funding,” said Glenda Gray, who is spearheading an HIV vaccine trial by the SAMRC that received a multi-year grant of $45.6 million from the US Agency for International Development in 2023 to carry out the trial in eight African countries. However, USAID funding was halted this year, resulting in a loss of most financial support.
In South Africa, where roughly 13% of the 62 million population is infected with the HIV virus that causes AIDS, the nation is leading research into sexually transmitted infections and other significant health issues common in developing countries, such as TB. Gray has indicated that the trial might need to be scaled down to maintain its operations.
Read: Treasury hands HIV response a lifeline
The funding is intended to assist research and academic institutions with existing US grants that have been adversely affected by the withdrawal of US funding, as stated by the SAMRC.
© 2025 Bloomberg
Follow Moneyweb’s in-depth finance and business news on WhatsApp here.
